Cumulus NeuLogiq ALS FTD Study Published

Cumulus Neuroscience announced the publication of final results from its CNS-102 study in Scientific Reports, demonstrating that its at-home NeuLogiq Platform is feasible, well tolerated, and highly usable for multimodal cognitive assessment in people living with ALS and FTD. The study, conducted with the PRECISIONALS initiative hosted by Trinity College Dublin, combined at-home EEG with a multi-domain cognitive battery, a first for this patient population. Among 28 participants, the ALS group reported high usability (mean SUS=89), with 82% rating the platform easy to use and 75% positive overall. The platform distinguished ALS, FTD, and control groups at baseline with effect sizes comparable to clinician-administered batteries, and exploratory longitudinal signals on speech fluency and emotion recognition were observed in the ALS group. The study was developed with a consortium of pharmaceutical companies including Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, GSK, and Takeda. This publication supports the NeuLogiq platform's potential to provide more sensitive, patient-centered endpoints for future ALS and FTD trials.